Neuralink
PrivateLast Round
Series E
May 27, 2025
Est. Valuation
$9.6B
Total Funding Raised
$1.34B
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neuralink is a neurotechnology company that develops implantable brain-machine interfaces aimed at assisting individuals with paralysis and addressing neurological conditions while potentially enhancing cognitive abilities.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Health IoT, Medical AI
Business Model
B2B2C
Customer Profile
Hardware Sales, Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Keywords
Price History
Caplight MarketPrice™ estimate for Neuralink, published with a 90-day delay.
Caplight MarketPrice™
$236.10
per share, as of April 2026
+474.8%
2-year change
Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.
Neuralink Comparables
Compare Neuralink with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synchron | 84% | |
| Precision Neuroscience | 81% | |
| Paradromics | 80% | |
Neuralink Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | May 27, 2025 | ||||
| Series D Extension | Nov 22, 2023 | ||||
| Series D | Aug 5, 2023 | ||||
| Series C | Jul 29, 2021 | ||||
| Growth Equity | May 10, 2019 | ||||
Series A | Aug 1, 2017 |
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
OFFER | |||||
BID | |||||
BID | |||||
BID | |||||
OFFER | |||||
BID |
Key People
Founding team and executive leadership
Neuralink Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series E |
| Time BioVentures | Series C |
| GV | Series C |
| Craft Ventures | Series C |
| CoreNest | Series E |
| Founders Fund | Series C, Series E, Series D, Series D Extension |
| Thrive Capital | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Blackrock Neurotech was mentioned as one of a few BCI companies to have received Breakthrough Device designation from the FDA to date.
- Apr 9, 2026
Synchron was mentioned as one of a few BCI companies to have received Breakthrough Device designation from the FDA to date.
Neuralink Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Neuralink's valuation, stock price, and market status.